6885.TW BRIM Biotechnology, Inc.
- Market cap
- TWD 3.55B
- P/E
- -
- P/B
- 2.30x
- ROE
- -23.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6885.TW undervalued?
Graham numberThe Graham number of BRIM Biotechnology, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BRIM Biotechnology, Inc. fundamental analysis
No fundamental analysis for BRIM Biotechnology, Inc. yet.
BRIM Biotechnology, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BRIM Biotechnology, Inc.
BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for…
Full company profileBRIM Biotechnology, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BRIM Biotechnology, Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 360K | 526K | 90.0K | 333K | 5.49M | 13.6M |
| Gross Profit | 360K | 526K | 90.0K | 22.0K | 1.25M | -2.33M |
| Operating Income | -93.2M | -218M | -694M | -345M | -453M | -339M |
| EBITDA | - | -270M | -682M | -306M | -407M | -359M |
| Net Income | -105M | -274M | -688M | -315M | -436M | -365M |
| EPS | -1.36 | -2.84 | -5.94 | -2.40 | -3.28 | -2.75 |
| Balance Sheet | ||||||
| Total Assets | 495M | 940M | 1.78B | 2.41B | 1.83B | 1.66B |
| Total Liabilities | 17.6M | 25.3M | 42.2M | 354M | 74.1M | 42.9M |
| Shareholders' Equity | 478M | 915M | 1.74B | 2.06B | 1.66B | 1.54B |
| Cash & Short-term Investments | 400M | 838M | 948M | 503M | 798M | 299M |
| Cash Flow | ||||||
| Operating Cash Flow | -113M | -172M | -597M | -279M | -329M | -315M |
| Capital Expenditure | 514K | 1.21M | 3.70M | 80.0M | 325M | 28.4M |
| Free Cash Flow | -113M | -173M | -601M | -359M | -654M | -344M |
| Ratios | ||||||
| ROE | -22.1% | -30.0% | -39.6% | -15.3% | -26.4% | -23.7% |
| ROA | -21.3% | -29.2% | -38.7% | -13.1% | -23.9% | -22.0% |
| Net Profit Margin | -29,291.4% | -52,143.9% | -764,468.9% | -94,735.7% | -7,949.9% | -2,690.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BRIM Biotechnology, Inc. dividends
BRIM Biotechnology, Inc. has not paid dividends in the last 5 fiscal years.
Who owns BRIM Biotechnology, Inc.
- Insiders 23.12%
- Institutions 0.22%
- Public & others 76.66%
- Shares outstanding 133M
- Free float 113M
BRIM Biotechnology, Inc. company profile
- Company name
- BRIM Biotechnology, Inc.
- Ticker
- 6885.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 32
- Fiscal year end
- December
- Address
- No.1, Alley 30, Taipei, Taiwan, 11492
- Phone
- 886 2 2659 8586
- Website
- brimbiotech.com
About BRIM Biotechnology, Inc.
BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that has completed Phase 2 clinical trial to treat wet age-related macular degeneration; and BRM521, a PEDF-derived short peptide that is in pre-clinical trial to relieve and repair tissue damage caused by osteoarthritis. BRIM Biotechnology, Inc. was founded in 2013 and is based in Taipei, Taiwan.
BRIM Biotechnology, Inc. management
4- Mr. Qun Lin M.B.A., M.S.Chairman & Chief Investment Officer
- Dr. Frank W. Lee Ph.D.Chief Scientific Officer · born 1951
- Dr. Wenqi Xu Ph.D.CEO & GM
- Ms. Yi-Chun ChenVice President of Business Development